• Sensei Biotherapeutics dosed first patient in Phase 1b/2 Study FTH-PIK-101 of investigational PIKTOR for HR+/HER2- advanced breast cancer.
• Trial will test oral serabelisib and sapanisertib combination with fulvestrant or other anticancer therapies, aiming to curb disease progression in tumors that no longer respond to standard options.
• No new results were presented; study is starting, with outcomes expected in future readouts.
• Company pointed to earlier testing of PIKTOR in other solid tumors showing tumor shrinkage in some heavily pretreated patients, supporting expansion into breast cancer as lead program following February 2026 Faeth Therapeutics acquisition.
• Sensei also cited ongoing Phase 2 Study FTH-PIK-201 evaluating PIKTOR in advanced endometrial cancer.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sensei Biotherapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202605050730BIZWIRE_USPR_____20260505_BW524502) on May 05, 2026, and is solely responsible for the information contained therein.